From: A phase II trial of a biweekly combination of paclitaxel and gemcitabine in metastatic breast cancer
Characteristic | n(%) |
---|---|
Age (years) | |
Median | 51 |
Range | 39–69 |
P. S 0–1 | 20(80%) |
P. S 2 | 5 (20%) |
Histology | |
Infiltrating ductal ca | 19 (76) |
Infiltrating lobular ca | 6 (14) |
Estrogen status | |
ER+ | 14 (56) |
ER - | 7 (28) |
Unknown | 4 (16) |
Dominant sites of metastases | |
Nodes | 10(40) |
Soft tissues | 2(8) |
Bone | 5(20) |
Liver | 8(32) |
Lung | 7(28) |
Pretreatment with antracyclines | |
Adjuvant CT | 11(44) |
Not adjuvant CT | 14(56) |